When will Anduril officially announce an IPO?

Anduril's CEO confirms IPO plans amidst significant valuation discrepancies. Palmer Luckey has publicly stated that the company "definitely" intends to go public ^{[^]}. The company's valuation has been reported with considerable variation, ranging from $10.1 billion in early 2023, which was based on approximately $600 million in trailing twelve-month (TTM) revenue ^{[^]}, to more recent estimations as high as $28 billion ^{[^]} and $30.5 billion ^{[^]}.

Anduril shows strong revenue growth with future projections. The company reported $400 million in revenue during 2022, which subsequently increased to an estimated $600 million in 2023 ^{[^]}. Projections for 2024 further estimate revenues to reach approximately $1 billion ^{[^]} or $1.1 billion ^{[^]}, with some forecasts suggesting a potential increase to $2.2 billion by 2025 ^{[^]}.

Specific board-established financial targets remain undisclosed for IPO justification. Despite the varying valuations and revenue figures, the available research does not disclose specific TTM revenue or free cash flow margin targets that Anduril's board has established as the minimum financial threshold to justify an IPO valuation exceeding $12 billion.

Specific investor fund lifecycles remain unconfirmed, hindering liquidity event pressure assessment. Founders Fund is a significant investor in Anduril, having led a $2.5 billion funding round in June 2025 that valued the company at $30.5 billion ^{[^]}, ^{[^]}. While venture capital firms typically seek liquidity events within certain fund lifecycles to return capital to their limited partners, available sources do not provide specific fund lifecycle details for Founders Fund's investments in Anduril, nor do they detail Valor Equity Partners' involvement or fund lifecycles ^{[^]}, ^{[^]}, ^{[^]}, ^{[^]}, ^{[^]}. This absence of specific data makes it challenging to directly link investor fund lifecycles to pressure for a liquidity event by Q4 2026.

Market predictions show low IPO probability before Q4 2026. Despite the potential for investor pressure, current market predictions suggest a low likelihood of an Anduril IPO occurring before Q4 2026 or 2027. One prediction market indicated only a 21% probability of Anduril having an IPO before 2027, with 79% predicting against it ^{[^]}. Additionally, another source noted a "plummeting" IPO probability for Anduril, citing "investor reality checks" within a "mixed 2026 IPO landscape" ^{[^]}. These market sentiments collectively indicate that a liquidity event, such as an IPO, is not strongly anticipated by the end of 2026.

Anduril's CEO confirmed IPO plans, actively pursuing major defense contracts. Palmer Luckey, CEO of Anduril, has publicly stated the company's intention to file an Initial Public Offering (IPO), positioning itself to compete for substantial "trillion-dollar defense contracts" ^{[^]}. The company is an active participant in the U.S. Air Force's Collaborative Combat Aircraft (CCA) program, having been selected in April 2024 for the next development phase ^{[^]}. The Air Force expects to select the first autonomous fighter by the end of the current year and plans to allocate nearly $1 billion to begin procuring CCA drones in 2027 ^{[^]}.

The CCA program's importance for Anduril is clear, yet a direct IPO link is not. While large defense contracts, such as the CCA program, are significant for Anduril's long-term financial health and growth, which would support a potential 2026 IPO with an estimated valuation of $30.5 billion ^{[^]}, the available research does not contain an explicit statement from company insiders directly linking the outcome or timing of the U.S. Air Force's final decision on the CCA program as a determinant for the 2026 IPO filing. Reports indicate that delays in the CCA program were attributed to a push for a 'semi-autonomous' first flight, projected for September 2025 ^{[^]}.

Anduril Industries seeks significant private funding at an ambitious valuation. The company is reportedly in discussions to raise a new private funding round of up to $8 billion, targeting a valuation exceeding $60 billion ^{[^]}. One report also indicated a target of $4 billion in funding aimed at doubling its valuation, which aligns with the aspiration for a $60 billion range and would significantly increase the company's previous approximate valuation of $30.5 billion ^{[^]}.

Sovereign wealth funds are capable of supporting a delayed IPO. These funds are well-positioned to lead or substantially contribute to such large private funding rounds, demonstrating significant capacity for investments in private companies ^{[^]}. The availability of private capital is crucial for delaying a public offering. Prediction markets show a high probability, approximately 79%, that Anduril's IPO will not occur before 2027 ^{[^]}. This market sentiment suggests that sufficient private funding is either expected or available at a valuation attractive enough to postpone a public listing for several years ^{[^]}.

Anduril has not publicly announced lead underwriter selection process. The company has not initiated a formal 'bake-off' to select lead underwriters, such as Goldman Sachs or Morgan Stanley. This procedural step often precedes an S-1 filing. While available sources discuss Anduril's intent to go public and its valuation, they do not detail specific progress on the underwriter selection process ^{[^]}.

Anduril has a permanent, experienced Chief Financial Officer. Babak Siavoshy has served as Anduril's permanent Chief Financial Officer since January 2022 ^{[^]}. Mr. Siavoshy's background includes 13 years at Goldman Sachs, where he reached the position of Vice President in investment banking, providing him with extensive exposure to public companies, capital markets, and the IPO process ^{[^]}. Prior to joining Anduril, he also served as CFO at two other companies ^{[^]}.

Catalyst analysis unavailable.